My initial thesis on Kroger (NYSE: KR ), which I put forward at the end of July , has actually only strengthened. In that article, I argued that the stock is clearly undervaluedHi there! I’m Narek, and I’ve been in the investment world for over six years. I started out as an equity analyst at European banks, digging into reports and learning how to spot value in the markets. I’ve worked across sectors — from telecom to industry — and found that behind every financial statement is a real story. I studied in ...

Group 1 - The analyst downgraded ASML Holding N.V. to a Hold rating in April due to technical weakness and a poor macroenvironment despite its undervaluation [1] - The analyst acknowledges that the focus should have been on ASML's undervaluation rather than the negative technical indicators [1] - The analyst emphasizes the importance of core values such as Excellence, Integrity, Transparency, and Respect for long-term success [1] Group 2 - The article does not provide specific financial data or performance metrics related to ASML or the tech sector [2]

Core Viewpoint - Copa Holdings (NYSE: CPA) has been initiated as a "Strong Buy" and has returned 26% since the recommendation, outperforming the market, yet the stock remains undervalued [1] Summary by Relevant Sections - **Stock Performance** - The stock has returned 26% including dividends since the initiation of coverage [1] - **Valuation** - Despite the positive price action, the stock is still considered undervalued, albeit to a lesser extent [1] - **Investment Philosophy** - The analysis reflects a long-term investment approach, emphasizing the importance of knowledge compounding and strategic thinking in investing [1]

Group 1 - Schlumberger may encounter challenges due to a softening production environment as new barrels enter the market through OPEC+ [1] - Despite potential market challenges, Schlumberger is finding strength in its operations [1] Group 2 - The article highlights the importance of considering the entire investment ecosystem rather than evaluating a company in isolation [1]

Group 1 - Nike, Inc. shares have declined over 35% year-to-date, resulting in a 10-year return of just over 10% [1] - The company has experienced a series of negative news impacting its stock performance [1] Group 2 - The focus of retail investors has been primarily on sectors like semiconductors and fintech, indicating a shift in investment interest away from traditional apparel stocks [1]

Market Overview - The American stock markets have experienced a downturn due to international tariff fears, impacting most sectors, while healthcare stocks have outperformed the general market in 2025 [1] Healthcare Sector Performance - Healthcare stocks are rising above competitors, with some appreciating by at least 30% this year, and smaller stocks seeing increases of 50% or more, indicating potential undervaluation [2] - Royalty Pharma has seen a 25% year-to-date price appreciation, with a current price of $31.37 and a 12-month price forecast of $41.60, suggesting a 32.61% upside [2][4] - CVS Health has experienced a 50% increase in share price since the beginning of the year, with a current price of $67.13 and a 12-month price forecast of $70.41, indicating a 4.89% upside [5][6] - Tempus AI has seen a 60% increase in share price year-to-date, with a current price of $47.83 and a 12-month price forecast of $61.18, suggesting a 27.92% upside [8][9] - Guardant Health's share prices have risen nearly 50% since the beginning of the year, with a current price of $43.14 and a 12-month price forecast of $48.95, indicating a 13.47% upside [11][12] Institutional Investments and Analyst Ratings - Royalty Pharma has seen significant institutional buying, with purchases rising to $748 million in Q4 2024 from $177 million in Q3 2024, and maintains a Buy rating from analysts [3] - CVS Health's short interest has fallen by over 12%, indicating increased investor confidence, and it has a Moderate Buy rating from analysts [7] - Tempus AI's quarterly revenue increased by 35.8% year-over-year to $200.7 million, with gross profit rising by 49.7% to $122.1 million, contributing to its positive analyst ratings [9][10] - Guardant Health has a consensus Buy rating from analysts, with actual revenue consistently beating estimates, although its path to profitability remains uncertain [13][14]